Clinical Outcomes of Radiotherapy for Stage 1 Glottic Carcinoma: Comparing Accelerated Hyperfractionation and Once-daily Fractionation
- PMID: 37652523
- PMCID: PMC10500519
- DOI: 10.21873/invivo.13335
Clinical Outcomes of Radiotherapy for Stage 1 Glottic Carcinoma: Comparing Accelerated Hyperfractionation and Once-daily Fractionation
Abstract
Background/aim: Accelerated hyperfractionation (AHF) is used in head and neck cancer to improve the local control (LC) rate, but reports of outcomes for early-stage GC are limited. The outcomes of radiotherapy (RT) for stage 1 glottic carcinoma (GC) were retrospectively analyzed, comparing AHF and once-daily fractionation (ODF) using 2.0-2.4 Gy.
Patients and methods: A total of 102 patients with stage 1 GC underwent RT alone between 2007 and 2021, with 43 in the AHF group and 59 in the ODF group. A p-value less than 0.05 was considered to indicate a significant difference.
Results: The 5-year LC rate was 98% in the AHF group and 91% in the ODF group (p=0.19). During RT, significantly more patients in the AHF group required opioids due to mucositis than in the ODF group (74% vs. 25%, p<0.001), and the rate of aspiration pneumonia tended to be higher in the AHF group than in the ODF group (7% vs. 0%, p=0.072).
Conclusion: There was no difference in the LC rate between AHF and ODF for stage 1 GC. Moreover, the AHF group required opioids at a higher rate and tended to have a higher risk of developing aspiration pneumonia.
Keywords: Glottic cancer; accelerated hyperfractionation; aspiration pneumonia; opioid; radiotherapy.
Copyright © 2023, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Conflict of interest statement
The Authors declared no potential conflicts of interest concerning this research, authorship, and/or publication.
Figures



Similar articles
-
Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation.Br J Cancer. 2002 Feb 12;86(4):517-23. doi: 10.1038/sj.bjc.6600119. Br J Cancer. 2002. PMID: 11870530 Free PMC article. Clinical Trial.
-
Esophageal cancer treated with radiotherapy: impact of total treatment time and fractionation.Int J Radiat Oncol Biol Phys. 1994 Dec 1;30(5):1099-105. doi: 10.1016/0360-3016(94)90315-8. Int J Radiat Oncol Biol Phys. 1994. PMID: 7961017 Clinical Trial.
-
Advantage of accelerated fractionation regimens in definitive radiotherapy for stage II glottic carcinoma.Ann Otol Rhinol Laryngol. 2006 Oct;115(10):727-32. doi: 10.1177/000348940611501003. Ann Otol Rhinol Laryngol. 2006. PMID: 17076093
-
Altered-fractionation radiotherapy improves local control in early-stage glottic carcinoma: A systematic review and meta-analysis of 1762 patients.Oral Oncol. 2019 Jun;93:8-14. doi: 10.1016/j.oraloncology.2019.04.007. Epub 2019 Apr 8. Oral Oncol. 2019. PMID: 31109700
-
Effect of radiation fraction size on local control rates for early glottic carcinoma. A model analysis for in vivo tumor growth and radio-response parameters.Arch Otolaryngol Head Neck Surg. 1994 Jul;120(7):737-42. doi: 10.1001/archotol.1994.01880310041008. Arch Otolaryngol Head Neck Surg. 1994. PMID: 8018326 Review.
References
-
- Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, Horiot J, Le Maître A, Pajak TF, Poulsen MG, O’sullivan B, Dobrowsky W, Hliniak A, Skladowski K, Hay JH, Pinto LH, Fallai C, Fu KK, Sylvester R, Pignon J. Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis. Lancet. 2006;368(9538):843–854. doi: 10.1016/S0140-6736(06)69121-6. - DOI - PubMed
-
- Sugawara T, Masanori N, Kiyoshi O, Takeshi S. The effect of overall on locoregional tumor treatment time control in patients. J Japanese Soc Ther Radiol Oncol. 1996;8:293–301.
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous